Company intelligence / Profile preview

P4 Therapeutics

Vienna, Vienna, Austriabionity.com ↗

Ownership: Private
Development stage: Preclinical

Overview

P4 Therapeutics GmbH focuses on developing next-generation platinum-based anticancer drugs. Their lead project, Albuplatin, aims to improve the efficacy and safety profile of traditional platinum chemotherapies. The company appears to be in the pre-clinical research phase with no reported clinical results yet[1][2].

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on P4 Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on P4 Therapeutics.

Explore the full profile